Targovax – Therapeutic cancer vaccines

Targovax is an innovation driven specialist in immuno-oncology.

People with identical cancer diagnoses do not have identical diseases. Their cells vary in the way they look, function and are seen by the immune system – the body’s own defence against cancer. At Targovax, we are developing cancer specific therapies that activate each patient’s own immune system to fight against their disease.

Read more

Even in late stage cancer patients with low immunogenic tumor types, our virus-based immunotherapy can reinstate the immune system’s ability to recognize and attack cancer cells. In addition, studies with our peptide-based Immunotherapy have shown immune responses in difficult to treat RAS cancer patients.

Read more

8 July Targovax got listed on Oslo Axess. Prospectus for the listing on Oslo Axess and a complete description of all conditions for the subsequent offering can be downloaded here.

Read more
  • Targovax to present at Redeye's Fight Cancer conference

    September 19, 2016

    Oslo, Norway, 19 September 2016: Targovax (OSE: TRVX), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management will present at the following conference:

    Redeye: Fight Cancer - Immuno-oncology
    Date: 20 September 2016
    P (...)

    Read more
  • Targovax to present at forthcoming conferences

    September 14, 2016

    Oslo 14 September 2016: Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management will present at the following conferences:

    Nordic Life Science Days
    Date: 14 September 2016
    Parti (...)

    Read more
  • Targovax ASA: Interim Report second quarter and first half year 2016

    August 25, 2016

    Oslo, Norway, 25 August 2016 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for investors, analysts and press will take place in Oslo today (...)

    Read more
  • Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August

    August 15, 2016

    Oslo, Norway, 15 August 2016 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, will announce its second quarter and first half year 2016 results on Thursday, 25 August 2016. A presentation by Targovax's senior manag (...)

    Read more
  • Anne-Sophie Møller joins Targovax

    August 4, 2016

    Targovax has the pleasure of announcing Anne-Sophie Møllers appointment as Director of Clinical Science.

    Anne-Sophie has an MSc and a PhD in Cell Biology and Immunology, both from the University of Oslo bringing over 25 years of both academic and commercial research experience to Targovax. She joins us from Thermo Fischer Life Technologies where she was the Senior Manager of Method Development & Quality Control. Her academic career includes working at Århus University in Denmark, the University of Oslo and the Norwegian Radium Hospital in addition to over ten years in the pharmaceutical industry with Nycomed Pharma and Thermo Fisher.

    Anne-Sophie will lead our pre-clinical and clinical science department from our Oslo office starting 1st August.

    We are very happy to welcome Anne-Sophie to the team here at Targovax.

    Read more
  • Targovax ASA: Publication of prospectus, listing on Oslo Axess and subsequent offering

    July 8, 2016

    NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT

    Os (...)

    Read more